1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

 
• By Jessica Merrill

The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.

Cancer

AstraZeneca PLC and Daiichi Sankyo Co., Ltd. teased the possibility that the Phase III DESTINY-Breast04 study testing Enhertu (trastuzumab deruxtecan) in individuals with breast cancer categorized as HER-2 low was potentially paradigm-changing months ago with the release of top-line data, and the level of benefit seen in the full data presented at the American Society of Clinical Oncology (ASCO) meeting on 5 June clinched it.

The data are poised to change the way doctors think about categorizing breast cancer nearly 25 years after Genentech, Inc. launched the first HER2-targeted drug for breast cancer,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

More from Conferences

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.